

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
19 April 2007 (19.04.2007)

PCT

(10) International Publication Number  
**WO 2007/042239 A1**

(51) International Patent Classification:  
**C07D 207/22** (2006.01) **A61P 25/24** (2006.01)  
**A61K 31/401** (2006.01)

(74) Agent: **GIDDINGS, Peter, John**; GlaxoSmithKline,  
Corporate Intellectual Property, CN925.1, 980 Great West  
Road, Brentford Middlesex TW8 9GS (GB).

(21) International Application Number:  
PCT/EP2006/009731

(22) International Filing Date: 6 October 2006 (06.10.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0520581.0 10 October 2005 (10.10.2005) GB  
0523045.3 11 November 2005 (11.11.2005) GB  
0603900.2 27 February 2006 (27.02.2006) GB  
0618336.2 18 September 2006 (18.09.2006) GB

(71) Applicant (for all designated States except US): **GLAXO GROUP LIMITED** [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford Middlesex UB6 0NN (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ALVARO, Giuseppe** [IT/IT]; GlaxoSmithKline SpA, Via Alessandro Fleming 2, I-37135 Verona (IT). **BERGAUER, Markus** [DE/IT]; GlaxoSmithKline SpA, Via Alessandro Fleming 2, I-37135 Verona (IT). **GIOVANNINI, Riccardo** [IT/IT]; GlaxoSmithKline SpA, Via Alessandro Fleming 2, I-37135 Verona (IT). **PROFETA, Roberto** [IT/IT]; GlaxoSmithKline SpA, Via Alessandro Fleming 2, I-37135 Verona (IT).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:


— of inventorship (Rule 4.17(iv))

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PROLINAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS



(I)

(57) Abstract: The invention provides a compound of formula (I), a solvate, a salt or prodrug thereof, useful in the treatment of diseases and conditions mediated by modulation of use-dependent voltage-gated sodium channels.

WO 2007/042239 A1